660MO A phase I, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: The REGOMA-2 trial.
Saved in:
| Title: | 660MO A phase I, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: The REGOMA-2 trial. |
|---|---|
| Authors: | Padovan, M.1 (AUTHOR), Simonelli, M.2 (AUTHOR), De Nicolò, A.3 (AUTHOR), Del Bianco, P.4 (AUTHOR), Cerretti, G.1 (AUTHOR), Caccese, M.1 (AUTHOR), Persico, P.2 (AUTHOR), Menegatti, G.3 (AUTHOR), Bosio, A.1 (AUTHOR), Dipasquale, A.2 (AUTHOR), Maccari, M.1 (AUTHOR), Losurdo, A.2 (AUTHOR), Coppola, M.5 (AUTHOR), Krengli, M.6 (AUTHOR), Lonardi, S.1 (AUTHOR), D'Avolio, A.3 (AUTHOR), De Salvo, G.4 (AUTHOR), Lombardi, G.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS482-S482. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189419051 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 660MO A phase I, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: The REGOMA-2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Padovan%2C+M%2E%22">Padovan, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Simonelli%2C+M%2E%22">Simonelli, M.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Nicolò%2C+A%2E%22">De Nicolò, A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Del+Bianco%2C+P%2E%22">Del Bianco, P.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cerretti%2C+G%2E%22">Cerretti, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Caccese%2C+M%2E%22">Caccese, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Persico%2C+P%2E%22">Persico, P.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Menegatti%2C+G%2E%22">Menegatti, G.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bosio%2C+A%2E%22">Bosio, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dipasquale%2C+A%2E%22">Dipasquale, A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Maccari%2C+M%2E%22">Maccari, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Losurdo%2C+A%2E%22">Losurdo, A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coppola%2C+M%2E%22">Coppola, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krengli%2C+M%2E%22">Krengli, M.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lonardi%2C+S%2E%22">Lonardi, S.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22D'Avolio%2C+A%2E%22">D'Avolio, A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Salvo%2C+G%2E%22">De Salvo, G.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lombardi%2C+G%2E%22">Lombardi, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS482-S482. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189419051 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.1235 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S482 Titles: – TitleFull: 660MO A phase I, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: The REGOMA-2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Padovan, M. – PersonEntity: Name: NameFull: Simonelli, M. – PersonEntity: Name: NameFull: De Nicolò, A. – PersonEntity: Name: NameFull: Del Bianco, P. – PersonEntity: Name: NameFull: Cerretti, G. – PersonEntity: Name: NameFull: Caccese, M. – PersonEntity: Name: NameFull: Persico, P. – PersonEntity: Name: NameFull: Menegatti, G. – PersonEntity: Name: NameFull: Bosio, A. – PersonEntity: Name: NameFull: Dipasquale, A. – PersonEntity: Name: NameFull: Maccari, M. – PersonEntity: Name: NameFull: Losurdo, A. – PersonEntity: Name: NameFull: Coppola, M. – PersonEntity: Name: NameFull: Krengli, M. – PersonEntity: Name: NameFull: Lonardi, S. – PersonEntity: Name: NameFull: D'Avolio, A. – PersonEntity: Name: NameFull: De Salvo, G. – PersonEntity: Name: NameFull: Lombardi, G. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |